Background <p>Neoadjuvant PD-1/PD-L1 blockade yields robust efficacy in advanced cutaneous squamous cell carcinoma (cSCC), yet many patients fail to achieve a complete or major pathologic response. The reasons why some patients experience response but others do not are unclear.</p> Methods <p>We profiled cSCC specimens before, after 1 dose, and after 3–4 doses of PD-1/PD-L1 blockade to uncover resistance mechanisms and…
Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma
Journal for ImmunoTherapy of Cancer | | Lee, M. Y., Sherman, A. R., Martinez Ramirez, L., Rahman, M., Zdravkovic, S., Shin, J. H., Stepanek, I., Colevas, A. D., Sunwoo, J. B., Divi, V.
Topics: cervical-cancer, immunotherapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer